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Abstract
Background: The capacity of a polypeptide chain to engage in an amyloid formation process and cause a conformational
disease is contained in its sequence. Some of the sequences undergoing fibrillation contain critical methionine (Met)
residues which in vivo can be synthetically substituted by selenomethionine (SeM) and alter their properties.
Methodology/Principal Findings: Using peptide synthesis, biophysical techniques and cell viability determinations we have
studied the effect of the substitution of methionine (Met) by selenomethionine (SeM) on the fibrillogenesis and toxic
properties of Ab40 and HuPrP(106–140). We have found that the effects display site-specificity and vary from inhibition of
fibrillation and decreased toxicity ([SeM35]Ab40, [SeM129]HuPrP(106–140) and [SeM134]HuPrP(106–140)), retarded assembly,
modulation of polymer shape and retention of toxicity ([SeM112]HuPrP(106–140) to absence of effects ([SeM109]HuPrP(106–
140)).
Conclusions/Significance: This work provides direct evidence that the substitution of Met by SeM in proamyloid sequences
has a major impact on their self-assembly and toxic properties, suggesting that the SeM pool can play a major role in
dictating the allowance and efficiency of a polypeptide chain to undergo toxic polymerization.
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Introduction
Protein conformational diseases share the occurrence of a basic
misfolding event that leads to the accumulation of proteins or
fragments thereof as distinct oligomeric self-assemblies with gained
toxic functions [1–3]. Among the various assemblies, amyloids
refer to highly ordered cross b-sheet fibrillar aggregates resulting
from tight interfacing of complementary b-sheets [4–7]. Despite
the regulation by covalent modifications such as proteolytic
cleavage, glycosilation and oxidation, among others, the gross
information dictating the capacity of a polypeptide chain to form
an amyloid is contained in its sequence [4,5,8]. Therefore,
deciphering the rules for modulating these sequences, their
conformation and their self-assembly preferences is fundamental
for the design of preventive therapies.
Among the different strategies for modifying protein sequences,
the replacement of Met residues by SeM is unique in that it occurs
in the absence of changes at the nucleic acid level [9,10]. Like Met,
SeM is an essential amino acid for humans and its availability is
strictly related to diet [9,11,12]. SeM incorporates non-specifically
into proteins in competition with Met [12]. As an organic part of
the Se pool, the reduction of its levels has been correlated with an
enhanced risk of aging disorders [13–15]. In principle, Met
substitution by SeM is regarded as a structurally inert change that
is exploited for the phasing of macromolecular structures in X-ray
crystallography [10]. However, some reports indicate changes in
the stability of proteins due to the increased hydrophobicity and
distinct oxidation susceptibility of SeM compared to Met [16–21].
Thus, changes in the Met/SeM ratio can be considered as a source
of transient, metabolic or non-coded mutations and their effect on
proteins may vary as a function of residue location.
Of the various amyloid-forming sequences, the amyloid b
peptides (Ab40 and Ab42) and the PrP(106–140) region are
essential components of protein deposits in degenerative dementias
and share the presence of regulatory Met residues [22–32]. Ab40
and Ab42, produced by sequential proteolytic cleavage of the
amyloid b-protein precursor (APP) by b- and c-secretase,
accumulate both as extracellular amyloid deposits and synaptic
oligomers in Alzheimer disease (AD) [27]. In both Ab peptides,
Met35, through the oxidation of its side chain, modulates the
oligomerization kinetics, the shape of the final polymer (oligomer
vs amyloid fibril) and the neurotoxic function [26,33–37]. In prion
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protein amyloidoses such as Gerstmann-Straussler-Scheinker
syndrome and cerebral amyloid angiopathy, fragments overlap-
ping the 106–140 region of the cellular prion protein (PrPC) form
the specific amyloid deposits [23,29,38]. This sequence (HuPrP)
contains four Met residues (Met109, Met112, Met129, Met134)
flanking either side of the palindromic AGAAAAGA region
essential for assembly [38]. Of those, Met109 and Met112 are not
conserved in mammalian PrP sequences and their mutation to Val
does not impede fibrillation while it regulates the processing at the
a-cleavage site [29,30,39]. On the other hand Met129 and Met132
are polymorphic positions in human and deer, respectively, and
their substitution by Val or Leu regulates the disease phenotype
and the ability to recognize and amplify exogenous prions
[22,28,29,32,40].
To establish the role of Se intake as related to its specific
incorporation as SeM into amyloid forming sequences, we have
synthesized Ab40 and HuPrP(106–140) sequences containing SeM
as a replacement for Met. In contrast to the single Met35
substitution in Ab40, the presence of four methionines in
HuPrP(106–140) allows to investigate the role of the replacement
site on fibril formation. Herein we show that the substitution of
Met by SeM in Ab40 and HuPrP(106–140) regulates both amyloid
formation and toxicity. For HuPrP(106–140), the inhibitory effect
displays site-specificity, with the activity varying from inhibition of
fibrillation and decrease in toxicity ([SeM35]Ab40 and [SeM129]-
HuPrP(106–140)) to accelerated fibrillation and modulation of the
polymer shape with retention of toxicity ([SeM109]HuPrP(106–
140) and [SeM112]HuPrP(106–140)).
Results
SeM incorporation to amyloid sequences
Figure 1 shows the sequences of Ab40 and HuPrP(106–140),
both with amyloid-forming capacity and with one or more Met
residues with relevant roles [27,29]. The single methionine (Met35)
in Ab40 allowed an unambiguous SeM replacement, while the
four (Met109, Met112, Met129, Met134) in HuPrP(106–140) required
a more extensive investigation of the site-specificity of SeM
replacement. Hence, the wt HuPrP(106–140) sequence with four
SeM residues (all-M), a non-oxidizable variant sequence (all-V)
with all four Met residues mutated to Val, plus four analogs with
single SeM replacements at either position 109, 112, 129 or 134,
and Val at the other positions, were prepared. While all seven
peptide sequences are of a size generally regarded as viable for
solid phase synthesis methodologies, their well-known tendency to
aggregate clearly placed them in the ‘‘synthetically difficult’’
category [41]. This fact, plus the need for cost-effective handling of
the high-priced Fmoc-SeM building block, called for highly
optimized, state of the art synthetic strategies. Thus, for
[SeM35]Ab40, the O-acyl isopeptide approach [42] to difficult
sequences was applied, whereby a soluble precursor, 26-O-isoacyl-
[SeM35]Ab(1–40), was prepared and purified to near-homogene-
ity, then incubated at pH 7.4 to give the target peptide in
precipitate form. For its part, [SeM109,112,129,134]HuPrP(106–140)
(all-M), its all-Val counterpart and the four site-specifically SeM-
substituted analogs were efficiently assembled by microwave-
assisted solid phase synthesis on ChemMatrixH, a resin proven
successful in preventing aggregation during the synthesis of large,
complex peptides [43]. Peptides were successfully purified from the
crude material and their identity and homogeneity confirmed by
mass spectrometry [44]. Full details on the synthesis, purification
and analytical documentation of all peptides are given in the
Supporting Information S1 file.
SeM35 impedes Ab40 fibrillation
To investigate the ability of SeM to modify the aggregation
properties of Ab40 we set up a ThT binding kinetics assay. To this
end, either wt Ab40 (Met35) or [SeM35]Ab40 were incubated at 20–
40 mM concentration in PBS in the presence of 15 mM ThT and the
increase in fluorescence emission as consequence of its binding to
cross b-sheets was monitored (see methods). Figure 2A shows that
wt Ab40 at 20 mM and 30uC provokes a time-dependent increase in
ThT fluorescence compatible with the known fibrillation process
[45]. Importantly, the kinetic trace was reproducible in independent
experiments with different batches, with an average lag-phase of
1362 h. In contrast, incubation of [SeM35]Ab40 under similar
conditions did not cause any detectable change in ThT fluores-
cence. Increasing [SeM35]Ab40 concentration up to 200 mM and
the incubation time up to 1 week did not provoke any significant or
additional change. These results suggest that the substitution of Met
by SeM has a clear deleterious impact on amyloid formation.
To confirm the previous findings we analyzed the reaction
products by Atomic Force Microscopy (AFM). Figure 2C shows
that, as expected from the ThT fluorescence readings, Ab40
assembles into long (.200 nm length) and thin (7 nm height and
about 2640 nm diameter) fibrils that appear decorated by
globular particles of about 4 nm in height and 40–80 nm in
diameter [Figure 2C insert]. In contrast, [SeM35]Ab40
uniquely yields globular aggregates characterized by 3.5–7 nm
height and 35 nm average diameter, corroborating the impair-
ment of the fibrillation process. On the other hand, [SeM35]Ab40
aggregates yielded electrophoretic patterns different from those of
toxic Ab40 oligomers [Figure 2B] [46].
SeM effect on fibrillation displays site-specificity
To ascertain whether the previous findings are uniquely related
to the Ab40 sequence and the essential role played by Met35, or
can take place also in other sequences, we analyzed the effect of
this substitution on the fibrillation properties of HuPrP(106–140).
In this case, given the presence of four Met residues and the
possible interference of undesired oxidations in long time
incubations, we investigated a non-oxidizable version (all-V, all
four Met replaced by Val), as well as single SeM replacements with
Val at the other positions [Figure 1].
Figure 3A shows that, at 30uC, 20 mM concentration in PBS
and with mild orbital shaking, both all-M and all-V HuPrP(106–
140) undergo fibrillation, though with notable kinetic differences.
Thus, all-M HuPrP(106–140) exhibits the kinetic profile of a
highly cooperative process, characterized by an average lag time of
33.862.0 h and a final arbitrary ThT fluorescence intensity of
6065, whereas fibrillation of the all-V variant is characterized by a
lag-phase of about 16.462.0 h and a final ThT intensity reading
of 4064 [Figures 3A and 3B]. These differences found here for
the (106–140) sequence regions agree with previous findings
reporting the faster polymerization of [Val129]PrP compared to
[Met129]PrP and the higher propensity of [Met129]PrP(109–135)
over its Val129 variant to form b-sheet stabilized fibers [40,47].
Placing SeM at position 109 slightly reduces both the lag phase
and the final ThT intensity of the fibrillation kinetics. However,
the absence of a clear statistical significance in these changes
suggests that SeM109 behaves as an all-Val variant. On the
contrary, placing SeM at position 112 significantly increases the
lag time to 19.761.2 h with no effects in the maximum ThT
intensity. Surprisingly, the introduction of SeM at position 129
drastically impairs the fibrillation process. Prolonged incubations
(up to 1 week) yielded ThT intensity increases below 2.5 with
averaged lag phases of .72 h. Along similar lines but to a lesser
extent, placing SeM at position 134 allowed a slight fibrillation
Selenomethionine Regulates Amyloid Formation
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process featured by a final ThT intensity of 8 and a lag time of
31.562.0 h.
To confirm these findings we analyzed by AFM the products of
the aggregation reactions [Figure 3C]. In agreement with the
ThT kinetics, the all-M, all-V, SeM109 and SeM112 versions of
HuPrP(106–140) yielded fibrillar structures, of which those formed
by SeM112 differed notably from the others by appearing as
regular straight rods with a high homogeneity in length. On the
contrary, the reaction product of the SeM129 analog yielded
mainly amorphous aggregates with rarely the presence of fibrillar
aggregates. The SeM134 peptide displayed an intermediate
behaviour, showing few but detectable fibrillar assemblies. The
aggregation profile was also studied by SDS-PAGE. Figure 4A
shows that on aggregation all-M, all-V, SeM109 and SeM112
versions of PrP(106–140) yielded bands of SDS-resistant aggre-
gated species, whereas SeM129 and SeM134 ran mainly as
monomers.
Taken together these data indicate that, as for the case of Ab40,
SeM incorporation also impairs HuPrP(106–140) fibrillation, but
in this case the inhibitory process is highly dependent on the
replacement site, with position 129 and to a lesser extent 134 being
essential in this respect.
SeM modulates fibril shape
As noted above, [SeM112]HuPrP(106–140) forms fibrillar
aggregates that differ notably from those obtained from all-M,
Figure 1. Proamyloid sequences used as templates for the substitution of Met by SeM. Residues are depicted following one-letter code
except for selenomethionine that is abbreviated as SeM.
doi:10.1371/journal.pone.0027999.g001
Figure 2. Effect of the incorporation of SeM on the Ab40 amyloid formation. (A) Fibrillation kinetics followed by ThT binding. The displayed
curves were obtained by continuous incubation of 20 mM peptide solutions in PBS containing 15 mM ThT at 30uC run in triplicate, and represent the
average of three independent experiments. (B) Representative silver-stained SDS-PAGE gel of [Met35]Ab40 and [SeM35]Ab40 before (pre) and after
80 h (post) of incubation under aggregating conditions. Arrows indicate the distinct oligomers. (C) AFM topography imaging of the aggregation
reaction products of [Met35]Ab40 and [SeM35]Ab40 after 80 h of incubation. Inserts displayed the magnification of a representative area of each case.
doi:10.1371/journal.pone.0027999.g002
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all-V and SeM109 peptides. To gain an insight on the basis of this
polymorphism, the fibrils were isolated from the aggregation
reactions by centrifugation and, after resuspension, were
characterized for their ThT binding on fibril molar basis and
by far-UV CD for comparison with previous reports [48]. It must
be noted that SeM129 and SeM134 peptides were not considered
in this study given their failure to form fibrils with minimal
efficiency.
Figure 4B shows that the fibrillar aggregates of all-M, all-V,
SeM109 and SeM112 recovered by centrifugation from the
aggregation reactions and resuspended to similar molar concen-
tration yield similar ThT intensity, and the minor variations are
not statistically significant. Figure 4C shows that the all-M, all-V
and SeM109 peptides shared a common spectrum, featured by a
double minimum at 208 and 220 nm suggesting an altered b-sheet
structure. On the contrary, the spectrum of the SeM112 analog
displayed the features of a pure b-sheet structure. The results thus
support that, depending on its incorporation site, SeM can
modulate the secondary structure and subsequently sculpture its
self-assembly shape.
Interestingly, these distinct spectral features have been previ-
ously reported for the R- and S-fibrils formed by the full length
PrP resulting from the aggregation using two different conditions
[48]. In fact the morphological and spectral features herein found
for the aggregates formed by the SeM112 analog resemble those
described for S-fibrils, which can be formed with the HaPrP but
not with the MoPrP [48,49]. Similarly, the features of the fibrils
formed by the all-M, all-V and SeM109 peptides resemble the
properties described for the R-fibrils which can be formed by both
HaPrP and MoPrP [48,49]. Among other sequence differences,
HaPrP and MoPrP differ in the residue at position 112, Met in
HaPrP and Val in MoPrP. Since Met though not Val can be
metabolically replaced by SeM, it is tempting to speculate that the
formation of S-fibrils could be dictated at least in part by the
presence of chains containing SeM in position 112, which can
uniquely occur with HaPrP, not with MoPrP.
SeM effects on fibrillation are unrelated to oxidation
As with Met, the SeM side chain can undergo oxidation to
selenoxide and selenone, and if so could drastically modify the
Figure 3. Effect of the incorporation of SeM in HuPrP(106–140) on its amyloid formation. (A) Representative fibrillation kinetics of
HuPrP(106–140) sequences followed by ThT binding. The color code of the traces is depicted as an insert in each panel. The displayed curves were
obtained by continuous incubation of 20 mM peptide solutions in PBS containing 15 mM ThT at 30uC run in triplicate, and represent the average of
three independent experiments. (B) Lag times of the fibrillation kinetics of HuPrP(106–140) and of its variants. Lag times were calculated
independently from each curve and analyzed statistically using the Student’s t-test tool provided by Origin 6 software: *, non-significant; **, P,0.05.
(C) Phase images of the molecular species formed after 80 h incubation of HuPrP(106–140) sequences. The displayed fields for all-V, all-M, SeM109 and
SeM112 sequences represent most frequent areas (9 out 10 analyzed 1 mm61 mm regions). For SeM129 and SeM134 the displayed fields represent the
minor hits (1 out of 20 analyzed 1 mm61 mm regions).
doi:10.1371/journal.pone.0027999.g003
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process of amyloid formation [26,33–37]. To investigate whether
the observed differences in fibrillation were related to SeM
oxidation we analyzed by MALDI FT-ICR the peptides before
and after the aggregation reaction. In all cases, m/z patterns of
pre-aggregated and post-aggregated samples were superimposable
and peaks reproduced the theoretical predicted charged masses
[Figure 5, Supporting Information]. Importantly, no peaks at
+16/+32 Da expected for the oxidized variants were detected
[Figure 5]. Despite the non-quantitative nature of the mass
spectrometry method, it plausible discards that undesired side
chain oxidations play a role in the amyloid formation traits.
SeM containing sequences also function as exogenous
fibrillation regulators
Consistent with the previous findings and with the fact that Met
substitution by SeM would be hardly ever quantitative under
physiological conditions, we next tested the capacity of the SeM-
containing sequences to modulate the amyloid formation process
of the unlabelled sequences. As amyloid formation can be
essentially view as a seeded-polymerization in which nucleation,
elongation and polymer fragmentation are critical steps, the SeM
effects could also provide mechanistic information [1–7]. The
results are shown in Figure 6.
Co-incubation of [SeM35]Ab40 with Ab40 and with its longer
and more fibrillogenic form Ab42 impaired their fibrillation
process [Figure 6A]. These impairments could not be attributed
to dilution since, in the absence of [SeM35]Ab40 and at equal
concentration, both Ab40 and Ab42 undergo fibrillation. Rather,
the results agreed with an inhibition process and suggested that
[SeM35]Ab40 interacts with Met35-bearing peptides, and halts
their productive aggregation through the formation of growth-
impaired oligomers.
Figure 4. Aggregation profiles of HuPrP(106–140) sequence variants. (A) Typical aggregation pattern of HuPrP(106–140) and of its variants
probed by silver-stained SDS-PAGE. Peptide aliquots (1 mg) before (pre) and after 80 h (post) of aggregation were separated in TGX-Precast BioRad
gels and then silver stained. (B) Normalized ThT binding of the insoluble aggregates formed by HuPrP(106–140) peptides. Aggregated peptides were
isolated as insoluble pellets of 30 min centrifugations at 15000 rpm, resuspended in PBS at 60 mM concentration. ThT binding of the resuspended
aggregates was measured by fluorescence at 20 mM peptide and 15 mM ThT concentrations. (C) Far-UV CD spectral features of the insoluble
aggregates formed by HuPrP(106–140) peptides. Insoluble pellets were prepared as in panel B in PBS and the spectra recorded at 60 mM. At least
three separate experiments were performed to confirm these results.
doi:10.1371/journal.pone.0027999.g004
Selenomethionine Regulates Amyloid Formation
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27999
Selenomethionine Regulates Amyloid Formation
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27999
Similarly, in the HuPrP(106–140) case, co-incubation of 10 mM
SeM129 analog with 10 mM of either all-M [Figure 6B] or all-V
[Figure 6C] peptides inhibited amyloid formation. Again, such
inhibitions could not be attributed to dilution effects, since the
latter peptides, at 10 mM and in the absence of the SeM129 analog,
yielded ThT binding kinetics compatible with fibrillation reac-
tions. Hence, the inhibition trend suggests that [SeM129]-
HuPrP(106–140), acting like a quencher, interacts with either
all-M or all-V HuPrP(106–140), giving rise to oligoheteromeric
species that do not sustain growth. This data agreed with previous
findings indicating the essential role of identity in position 129 for
the allowance of formation of a stable steric zipper [50].
On the contrary, [SeM134]HuPrP(106–140), of very low
efficiency in fibrillogenesis, when mixed with either all-M or all-
V does not alter significantly the ThT binding pattern of the
previous peptides [Figure 6B and 6C]. These results suggest that
SeM134 precludes stable interaction and therefore causes its
segregation. Since position 134 has not been found to play a
fundamental role in amyloid formation, then the segregating
behavior seems related to SeM hydrophobic properties and their
provoked reactions [5,51,52].
On the other hand, SeM109 and SeM112 when mixed 1:1 with
either all-V or all-M peptides altered the ThT binding kinetics,
imposing their characteristic lag-phase and allowing the final ThT
intensity of the SeM-free peptide [Figure 6B and 6C]. This
observation strongly suggests that positions 109 and 112 determine
the efficiency of seed formation and therefore the speed of the
polymerization reaction [1–7].
SeM-containing sequences can ameliorate toxicity
To investigate the structure–activity relationship of the SeM
substitutions we analyzed the effect of the aggregation reaction
products on the viability of rodent primary cortical neurons
[Figure 7]. For this purposes, the different peptides and their
combination were incubated for 80 h at 30uC at 0.10–0.15 mM in
PBS and then diluted to a final concentration of 10 mM in the cell
medium and allowed to incubate for 48 h. Under the assay
conditions, all peptides except [SeM35]Ab40 and the SeM129 and
SeM134-analogs of HuPrP(106–140) and their mixtures have
completed their fibrillation process as judged by parallel ThT
reading, and the untreated cells yielded cell viability values that
amounted to 97.561%.
Ab40 was found to cause 1161% cell death, in agreement with
previous reports [27,37,53]. Interestingly, [SeM35]Ab40 reduced
cell death to 361.5%, thereby excluding any relationship between
its assemblies and the highly neurotoxic nonfibrillar oligomers
formed by Ab peptides [27]. This reduction pattern was
maintained for its 1:1 mixture with Ab40, which cannot be
explained solely on the basis of [Met35]Ab40 dilution as judged
from the concentration control.
As for HuPrP(106–140), the aggregation reaction products of
all-M and all-V caused about 2062% of cell death, in agreement
with the toxicity levels described for the polymers formed by
HuPrP(82–146) [54]. SeM109 and SeM112 analogs caused cell
death to a similar extent, in agreement with their similar amyloid
forming ability at long incubation times [Figure 3A]. On the
contrary, SeM129 and to a lesser extent SeM134 caused minor
effects on cell viability (1.160.5 and 460.6, respectively). As in the
case of [SeM35]Ab40, these statistically significant reductions in
the extent of cell death compared to that caused by the amyloid-
assembled sequences discards active oligomeric species. Moreover,
the aggregation products of the all-M and all-V peptides mixed
with SeM129 and SeM134 reproduced the profiles observed in
kinetic experiments [Figure 6B and 6C]. Mixing SeM129 1:1
with either all-M or all-V decreases cell death extent to almost
abrogation, and the effect cannot be explained solely in terms of
Figure 6. Analysis of the regulatory cross-talk between SeM-tagged and wt sequences. (A) ThT binding kinetics of Ab40 and Ab42 in the
absence (10 and 20 mM) and presence of [SeM35]Ab40 (10 mM of each peptide). (B) Time evolution of the ThT binding of mixtures of 10 mM all-M
HuPrP(106–126) in the absence and presence of 10 mM of HuPrP(106–126) sequence variants. (C) ThT binding kinetics of mixtures of 10 mM all-M
HuPrP(106–126) in the absence and presence of 10 mM of HuPrP 106–126 sequence variants. The color code of the different traces is indicated at the
right hand side of each panel. The displayed curves were obtained by continuous incubation of the different peptide solutions in PBS containing
15 mM ThT at 30uC in duplicate, and represent the average of three independent experiments.
doi:10.1371/journal.pone.0027999.g006
Figure 5. MALDI FT-ICR profiles of SeM-containing Ab40 and HuPrP(106–140) peptides. Representative m/z patterns of the distinct
peptides after 80 h of incubation under aggregating conditions. Measurements were performed using samples of at least two separate experiments.
Arrows indicate the theoretical positions for the m/z values of: 1) +1, 2) +16 (selenoxide), 3) +23 (Na+-adduct) and 4) +32 (selenone). For SeM35 the
values are: 4376.1, 4381.1, 4388.1, 4408.1. For SeM analogs of HuPrP(106–140) the values are: 3377.2, 3393.2, 3399.2, 3409,2. The peak complexity
arises from the Se isotopic distribution [20].
doi:10.1371/journal.pone.0027999.g005
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the reduction all-M and all-V concentration as shown by the
concentration controls. On the contrary, mixing the SeM134
analog 1:1 with either all-M or all-V reproduces the cell death
percentage of diluted all-M and all-V peptides.
Discussion
Unveiling the ways proamyloid sequences can be modulated to
impede their productive engagement into self-assembly processes
yielding toxic events is essential for designing preventing strategies for
conformational diseases. The pioneer study of Goldschmidt et al [5]
has solidly established as general principle that the capacity of a
protein to form the b-sheet based fibrillar amyloid structures is coded
in its sequence, although its display may depend on structural and
environmental regulatory factors [55]. One possible modulatory
event is that involving metabolic changes of Met and SeM pools and
consequently of their competitive incorporation in proteins through
the AUG codon. Taking the advantage of synthetic approaches we
have substituted Met by SeM in amyloid forming sequences and we
have found dramatic effects on their polymerization and toxicity.
These effects varied from inhibition ([SeM35]Ab40 and
[SeM129]PrP(106–140)), polymerization kinetics perturbation to
polymer shape determination ([SeM112]PrP(106–140)) [Figure 8].
Despite the consideration of Met and SeM as structurally
equivalent, the change of a sulfur by a selenium atom involves major
steric and reactivity differences. Se is slightly larger than S (atomic
radius of 1.17 vs 1.04 A˚) and has also a larger van der Waals radius
(1.90 vs 1.80 A˚).Since the spines of amyloid fibrils consist in steric
zippers formed by the interdigitation of b-sheets through their side
chains, any steric perturbation may lead to clashes which may
reduce the stability of this unit or even preclude its formation [5,50].
This might be the case of the fibrillation impairments of
[SeM35]Ab40 and [SeM129]PrP(106–140) peptides, for which the
crystal structure of shorter fragments have shown Met35 and Met129
actively participating in the inter-sheet packing [50,56]. Also, since
the interdigitations are not unique but can involve distinct patterns,
the side chain size increase together with its position can dictate the
preference for specific stacking patterns over others that as seeds will
produce distinct fibril shapes as for SeM109 and SeM112 analogs of
PrP(106–140) [5,50,56]. The larger size of Se than S also causes
SeM to have a larger surface area and hence hydrophobicity than
Met. Since amyloid formation is a complex process involving the
construction of oligomeric species undergoing growth, fragmenta-
tion and quenching or arrest, minor changes in hydrophobicity may
trigger significant alterations in the solubility of the distinct
oligomeric species as well as in the the features of the interacting
surfaces [1–7,50]. For instance, by its increased hydrophobicity
SeM can decrease the efficiency of amyloid formation in
[SeM134]PrP(106–140), which retains the ability to engage in the
process but does it with a very low efficiency.
SeM also differs from Met in its side chain oxidation process.
SeM can undergo oxidation by peroxynitrites to selenoxide but,
unlike the sulfoxide, the selenoxide is easily reduced by organic
thiols as glutathione and does not required enzymatic assistance
[20,52,57]. Although SeM oxidation is not a major event in our
experimental setup, since sulfoxide formation is known to impair
fibrillation in Ab40 and PrP(106–126), the chemical differences of
the reaction could add novel regulatory steps to the polymerization
[24–26,34,35,58]. To address this possibility, improved basic
knowledge is required on reaction conditions and product
characterization of SeM oxidation as a part of a protein and free
in solution [52,57].
For Ab40 the Met35SeM non-coded or metabolic mutation
impairs amyloid formation but stabilizes oligomeric assemblies as
shown by AFM. Based on shape considerations, the oligomers
might be suspected to act as the actual neurotoxins. However,
both PAGE-SDS analysis and toxicity evaluation discard such
assemblies being deleterious and support the importance of the
amyloid pathway as a source of toxic species. This rationale can be
extended to the [SeM129]HuPrP(106–140) analog, which in
addition to its impaired fibrillation and lack of toxic activity,
prevents the fibrillation and toxicity of all-V and all-M. For these
two cases, the incorporation of SeM into an essential position
functions as a physiological anti-amyloid metabolic defense.
However, the effect of SeM incorporation is not homogeneous.
For instance, the SeM109 and SeM112 analogs of HuPrP(106–140)
displayed differences in kinetics and in fibril shape, and such
morphological differences can have important functional implica-
Figure 8. Summary of the effects of SeM introduction in
amyloid forming sequences. Replacement of methionine (M)
residues by its metabolic competitor selenomethionine (SeM) in
proamyloid sequences involves changes in local hydrophobicity and
steric factors. With a site-dependence, the replacement can promote
side association reaction that either decrease the efficiency and speed
or impair amyloid formation. In other cases, by regulating the seed
packing can generate distinct fibrilar assemblies.
doi:10.1371/journal.pone.0027999.g008
Figure 7. Cytotoxic potential of SeM containing sequences and
of their mixtures. Rodent primary cortical neurons were cultured for 7
days on poly-D-lysine-coated coverslips and treated with 10 mM of each
peptide or 1:1 molar ratio mixture of peptides for 48 h. The cells were
then probed with LIVE/DEAD kit. The percentage of dead cells was
obtained dividing the number of dead cells by the total (live and dead)
number of cells. The results are the means 6 SD of three independent
experiments ran in duplicate. Statistical analysis was performed with the
Student’s t test tool of Origin software. ns, non-significant. *, P,0.05;
**, P,0.005.
doi:10.1371/journal.pone.0027999.g007
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tions [59]. In this sense, fibrils of the SeM112 –shape are expected
to be more toxic that fibrils with shapes of the SeM109-analog,
whereas if fragmented the toxicity profile inverts [59]. In our set
up, both assemblies yielded statistical similar toxicity traits
suggesting that SeM substitution could also play a role in the in
vivo stability (fragmentation or recycling) of the polymers so
activity differences in the 48 h assay become averaged. In this line,
H/D exchange experiments have shown that isolated fibrils can
display significant distinct recycling properties, with changes in
fibril dissolution rate constant of about two orders of magnitude (
0.6 s21 and 1.061022 s21 for Ab40 and Ab42, respectively) [60].
As summarized in Figure 8, these evidences clearly indicate
that SeM incorporation into pro-amyloid sequences results in
various effects as a function of its location and suggest that
metabolic changes in the Met/SeM pool can exert important
modulatory effects in amyloid diseases.
Materials and Methods
Peptides and aggregation reactions
The SeM-substituted versions of Ab40 and HuPrP(106–140)
(Figure 1A) were synthesized by solid phase methods, purified by
HPLC and characterized by mass spectrometry. Details are given
in the Supporting Information S1 file. For control studies,
Ab40 and Ab42 were obtained from GenScript. Lyophilized
peptide stocks were dissolved in HFIP, aliquoted and dried under
N2 for storage at 280uC. Samples were reconstituted in 5 mM
NH4OH pH 8.0 at about 2 mg/ml concentration and filtered
through 0.2 mm membranes before use. Peptide concentrations
were determined by UV spectroscopy and by amino acid analysis.
Peptide stock solutions were diluted with PBS at 100–200 mM
concentrations and kept at 4uC for less than 30 min. The
aggregation reactions were performed both in eppendorf tubes
and in wells of a 96-well plate by incubating 20–200 mM peptide
monomers in PBS at 30uC with orbital shaking (100 rpm).
Thioflavin T binding kinetics
The kinetics of thioflavin T (ThT) binding was monitored by
bottom reading of fluorescence intensity in a POLARstar
microplate reader (BMG Labtech) as described [51]. Measure-
ments were performed using 450 nm excitation and 480 nm
emission filters, 0.20 ml samples and 15 mM ThT concentration.
The measurement program consisted of 10 flashes reading every
10 min with 1-min of orbital 1-mm diameter shaking at 100 rpm
with the temperature controller set at 30uC. All measurements
were done in triplicate and the experiments were repeated at least
twice using two different peptide batches. When required, the lag-
phase was determined as described [61].
PAGE analysis
Peptide samples before and after 80 h of aggregation were
removed and diluted 1:1 in b-mercaptoethanol-free Laemmli buffer
and, omotting the thermal denaturation step, loaded in BioRad
precastTGX-gels. After silver staining, gel images were captured
and analyzed using the Molecular Imager ChemiDocTM XRS+
Imaging system and ImageLab 3.0.1 (beta2) software (BioRad).
Mass spectrometry analysis
Aliquots of the peptide solutions before and after aggregation
were removed, treated with HFIP for aggregate disruption and
analyzed using a-hydroxy-cinnamic acid matrix and a MALDI
FT-ICR 930-MS (Varian) instrument operating at 7 T and 1029
Torr and with OMEGA software.
Atomic force microscopy (AFM)
Ten ml-samples of peptide solution after 70 h incubation were
diluted to 2 mM with ddH2O and applied onto freshly cleaved
mica surfaces to adhere for 15 min. After washing with ddH2O,
samples were dried with N2. AFM imaging was then performed
using a PicoSPMTM (Molecular Imaging, Phoenix, AZ), operating
the AFM scanner in acoustic alternating current mode with Si,N-
ACT type cantilevers (ScienTec) with a tip radius ,10 nm and a
spring constant of 25–75 N/m [51]. The images (161 mm scans)
were collected at a scan rate of 1 line per second and analyzed
using WSxM 5.0 Nanotec software.
Circular dichroism (CD) spectroscopy
CD spectra were recorded in the far-UV region with a Jasco J-
810 spectropolarimeter in continuous scan mode (2502190 nm)
and a 0.1 cm path length quartz cuvette (Hellma) as described
previously [51].
Citotoxicity assays
Mice were obtained from the Centro de Biologı´a Molecular and
treated following the guidelines of Council of Europe Convention
ETS123, recently revised as indicated in the Directive 86/609/
EEC. Animal experiments were performed under protocols (P22/
P23) approved by the Centro de Biologı´a Molecular Severo Ochoa
Institutional Animal Care and Utilization Committee (CEEA-
CBM, Madrid, Spain). Primary cortical neurons were obtained
from the cerebral cortex of C57B16 E18 rat embryos, by
enzymatic dissociation with papain (Worthington Biochemical)
in EBSS for 45 min at 37uC. Cells were resuspended in
Neurobasal medium with 2% B27, 0.25% 200 mM Gln, 1%
Glutamax and 1% penicillin/streptomycin and seeded on cover
slips pre-coated with poly-D-Lys (10 mg/ml). Two days later,
5 mM Ara-C was added to the medium. Seven days later, peptides
preincubated in PBS were added at a final concentration of
25 mM. After 48 h incubation at 37uC, neuronal cell death was
determined using the LIVE/DEAD kit (Invitrogen) for mamma-
lian cells. Live cells (stained with calcein-AM) and dead cells
(stained with red-fluorescent ethidium homodimer-1) were count-
ed and the percentage of dead cells calculated.
Supporting Information
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